Search

Your search keyword '"Reiter, Edward O."' showing total 322 results
Start Over Author "Reiter, Edward O."
322 results on '"Reiter, Edward O."'

34. Growth hormone therapy in hypophosphatemic rickets

Author

Wilson, Darrell M., Lee, Phillip D.K., Morris, Alan H., Reiter, Edward O., Gertner, Joseph M., Marcus, Robert, Quarmby, Valerie E., and Rosenfeld, Ron G.

Subjects
Hypophosphatemia -- Care and treatment, Hypophosphatemia -- Drug therapy, Somatotropin -- Health aspects, Family and marriage, Health
Abstract

Familial hypophosphatemic rickets (FHPR) is a disorder characterized by abnormal phosphate transport in the kidney, persistent hypophosphatemia (low levels of phosphate in the blood), rickets (a disease of bone mineralization), and short stature. It is usually treated by high doses of phosphate and calcitriol (the active form of vitamin D, important in bone mineralization), but some evidence suggests that administering growth hormone could also be helpful. This was evaluated in a group of 11 children and adolescents (all with short stature) with FHPR who participated in a 10-week study during which they received, in sequence, no treatment, growth hormone only, and growth hormone plus phosphate and calcitriol. The nine youngest subjects continued to take growth hormone and conventional therapy (oral calcitriol and phosphate) for another six months after the study ended. Subjects' levels of growth hormone, phosphate, calcium, and other substances were monitored at regular intervals. During the growth hormone-treatment phase, subjects' blood phosphate levels increased to levels similar to those resulting from conventional therapy. The levels of alkaline phosphatase (an enzyme involved in bone remodeling) and osteocalcin, a protein whose concentrations probably reflect bone formation, also increased with growth hormone treatment. The subjects who took all three substances for six months had increased growth rate scores. Overall, the results suggest that growth hormone affects blood phosphate concentrations in a positive way. This could be of therapeutic benefit for people with FHPR; more investigations are needed to evaluate this possibility. (Consumer Summary produced by Reliance Medical Information, Inc.)

Published
1991

37. Literature abstract

Author

Wilson, Darrell M., Lee, Phillip D. K., Morris, Alan H., Reiter, Edward O., Gertner, Joseph M., Marcus, Robert, Quarmby, Valerie E., and Rosenfeld, Ron G.

Published
1993
Full Text
View/download PDF

38. Is Telephone Care an Effective Tool for Management of Children with Type 1 Diabetes?

Author

ALLEN, HOLLEY F., YARNIE, SHELLIE, MURRAY, MARY A., and REITER, EDWARD O.

Subjects
Diabetes in children -- Care and treatment, Type 1 diabetes -- Care and treatment, Telemedicine -- Usage, Physician and patient -- Communication, Health
Abstract

Intensive management of patients with type 1 diabetes improves control and reduces rates of long term complications. Telephone care as an adjunct to office visits is important in management of [...]

Published
2000

39. Type 3 renal tubular acidosis associated with growth hormone deficiency.

Author

Yin Ping Liew, Rogers, Timothy A., Garb, Jane L., Allen, Holley F., Reiter, Edward O., Campfield, Thomas J., Dharnidharka, Vikas R., and Braden, Gregory L.

Abstract

Background: We identified two boys with type 3 renal tubular acidosis (RTA) and growth hormone deficiency and we sought to differentiate them from children with classic type 1 distal RTA. Methods: We reviewed all children <6 years of age with RTA referred over a 13-year period and compared the growth response to alkali therapy in these two boys and in 28 children with only type 1 distal RTA. Results: All children with type 1 RTA reached the 5th percentile or higher on CDC growth charts within 2 years of alkali therapy. Their mean height standard deviation score (SDS) improved from -1.4 to -0.6 SDS and their mean mid-parental height (MPH) SDS improved from -0.6 to 0 SDS after 2 years. In contrast, the boys with growth hormone deficiency had a height SDS of -1.4 and -2.4 SDS after 2 years of alkali and the MPH SDS were both -2.6 SDS after 2 years of alkali therapy. Growth hormone therapy accelerated their growth to normal levels and led to longterm correction of RTA. Conclusions: A child with type 1 RTA whose height response after 2 years of alkali therapy is inadequate should undergo provocative growth hormone testing. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

46. Public Health Implications of Altered Puberty Timing

Author

Golub, Mari S., primary, Collman, Gwen W., additional, Foster, Paul M.D., additional, Kimmel, Carole A., additional, Rajpert-De Meyts, Ewa, additional, Reiter, Edward O., additional, Sharpe, Richard M., additional, Skakkebaek, Niels E., additional, and Toppari, Jorma, additional

Published
2008
Full Text
View/download PDF

48. Major Determinants of Height Development in Turner Syndrome (TS) Patients Treated With GH: Analysis of 987 Patients From KIGS

Author

Ranke, Michael B, primary, Lindberg, Anders, additional, Longás, Angel Ferrández, additional, Darendeliler, Feyza, additional, Albertsson-Wikland, Kerstin, additional, Dunger, David, additional, Cutfield, Wayne S, additional, Tauber, Maïthé, additional, Wilton, Patrick, additional, Wollmann, Hartmut A, additional, and Reiter, Edward O, additional

Published
2007
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results